Theravance drops rare disease drug after late-stage trial setback
Source: SeekingAlpha
2026-03-03 09:05:27 ET
More on Theravance Biopharma
- Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy - Slideshow
- Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript
- Seeking Alpha’s Quant Rating on Theravance Biopharma
- Historical earnings data for Theravance Biopharma
- Financial information for Theravance Biopharma
Read the full article on Seeking Alpha
For further details see:
Theravance drops rare disease drug after late-stage trial setback
Viatris Inc.
NASDAQ: VTRS
VTRS Trading
3.0% G/L:
$14.405 Last:
2,636,674 Volume:
$14.17 Open:
VTRS Latest News
February 27, 2026 03:57:23 pm
Bastion Bets on Government Spending with $8 Million New Stake in Parsons
February 26, 2026 06:55:00 am
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
VTRS Stock Data
$18,451,353,349
1,140,252,173
N/A
503
N/A
Pharmaceuticals
Healthcare
US
Canonsburg
